{"entity":{"id":"avc-101","kind":"drug","name":"AVC-101","aka":["UniCAR-T-CD123"],"tldr":"AVC-101 is an experimental autologous switchable CAR-T cell therapy from AvenCell Therapeutics, in phase 1 trials for relapsed or refractory acute myeloid leukaemia; its current status is not stated.","summary":"AVC-101 (UniCAR-T-CD123) is an autologous switchable CAR-T cell therapy (UniCAR, with separately dosed targeting module) from AvenCell Therapeutics, with AvenCell Europe GmbH as partner. Autologous CAR-T cells carrying a universal switchable receptor that is only active when a separately infused targeting module binds CD123 on leukaemia cells, so activity can be turned off and on. Its furthest stage is phase 1, for relapsed or refractory acute myeloid leukaemia. No clinical trial naming it is registered on ClinicalTrials.gov. Phase 1 dose escalation in relapsed/refractory AML reported at ASH 2023; AVC-101 is not on the current company pipeline page (which lists AVC-201, AVC-202, AVC-203). Registry trial of UniCAR02-T with TM123 (NCT04230265) is TERMINATED, 'business decision by sponsor'. It has not been shown to work in people.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"AvenCell Therapeutics: avencell.com","url":"https://avencell.com/avencell-raises-112-million-in-series-b-funding-led-by-novo-holdings/"},{"label":"AvenCell Therapeutics: avencell.com","url":"https://avencell.com/avencell-to-present-new-data-from-universal-switchable-car-t-cell-therapy-programs-at-65th-american-society-of-hematology-annual-meeting-and-exposition/"},{"label":"AvenCell Therapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/study/NCT04230265"}],"tags":["pipeline"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["cd123"],"drugs":[],"companies":["avencell-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"AVC-101","modality":"Autologous switchable CAR-T cell therapy (UniCAR, with separately dosed targeting module)","mechanism":"Autologous CAR-T cells carrying a universal switchable receptor that is only active when a separately infused targeting module binds CD123 on leukaemia cells, so activity can be turned off and on.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/avc-101/","neighbours":{"target":[{"id":"cd123","kind":"target","name":"CD123","route":"/targets/cd123/"}],"company":[{"id":"avencell-therapeutics","kind":"company","name":"AvenCell Therapeutics","route":"/companies/avencell-therapeutics/"}]}}